Skip to main content
Delfa

← All trials/NCT07244445

RecruitingPhase NA

Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy

Dietary Pistachio Intake and Nutrition-Related Outcomes in Individuals Using GLP-1 Receptor Agonists: A Randomized Controlled Trial

Lead sponsor

Ian J. Neeland, MD

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

1

Estimated enrollment

108

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥30

Primary endpoints

•Change is Satiety•Fatigue•Mood/well-being

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07244445
Org study IDSTUDY20250409

Timeline

Milestones

Study first posted2025-11-24actual
Study start2026-01-29actual
Last update posted2026-02-20actual
Primary completion2027-12estimated (month precision)
Study completion2027-12estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Individuals with a BMI ≥30 kg/m2 or with a BMI ≥27 kg/m2 with at least one weight-related comorbidity who have been continuously using semaglutide or tirzepatide for three months for a clinical indication and remain on the therapy at the time of enrollment

Exclusion criteria

•No use or contraindication to use of a GLP-1 RA
•Known allergy to nuts
•Pregnant or breastfeeding
•Incarcerated

Endpoints (18)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
8
Cardiometabolic biomarkers
4
Weight & body composition
3
Glycemic / diabetes
2
Patient-reported / QoL
1

Weight & body composition

3 endpoints
Secondary/protocol endpoint

Change in body weight as measured by medical record review

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Secondary/protocol endpoint

Change in waist circumference as measured by medical record review

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Secondary/protocol endpoint

Change in fat mass as measured by DEXA scan

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Change in fasting glucose as measured by medical record review

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Primary/protocol endpoint

Change in HbA1c as measured by medical record review

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Cardiometabolic biomarkers

4 endpoints
Primary/protocol endpoint

Change in total cholesterol as measured by medical record review

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Primary/protocol endpoint

Change in LDL-C as measured by medical record review

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Primary/protocol endpoint

Change in HDL-C as measured by medical record review

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Primary/protocol endpoint

Change in triglycerides as measured by medical record review

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Patient-reported / QoL

1 endpoint
Primary/protocol endpoint

Change in physical activity as measured by International Physical Activity Questionnaire (IPAQ)

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Other (unclassified)

8 endpoints
Primary/protocol endpoint/low confidence

Change is Satiety as measured by the Hunger and Satiety Visual Analog Scales (VAS)

Time frame:Baseline, End of study (12 weeks)

descriptive

Primary/protocol endpoint/low confidence

Change in fatigue as measured by the Fatigue Severity VAS-F Survey

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change in mood/well-being as measured by the Mental clarity, energy levels, and motivation VAS.

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change in dietary quality as measured by Healthy Eating Index (HEI)

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change in food enjoyment as measured by the Food Pleasure Scale (FPS)

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in hip circumference as measured by medical record review

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in lean body mass as measured by DEXA scan

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in overall body fat percentage as measured by DEXA scan

Time frame:Baseline, End of study (12 weeks)

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.